

Please amend the claims as follows:

*a2* 16. An isolated nucleic acid encoding [a peptide selected from the group consisting of] the peptide of claim 1[, the peptide of claim 2, the peptide of claim 3, the peptide of claim 4, and the peptide of claim 5].

*a3* 18. An expression vector comprising the isolated nucleic acid of claim [17] 16 operably linked to a promoter.

*a4* 21. A host cell transfected or transformed with [an expression vector selected from the group consisting of] the expression vector of claim 18[, the expression vector of claim 19, and the expression vector of claim 20].

*a5* 23. A method for enriching selectively a population of T lymphocytes with CD4<sup>+</sup> T lymphocytes specific for a MAGE-A1 HLA class II-binding peptide comprising:  
contacting an isolated population of T lymphocytes with an agent presenting a complex of the MAGE-A1 HLA class II-binding peptide of claim 1 and an HLA class II molecule in an amount sufficient to selectively enrich the isolated population of T lymphocytes with the CD4<sup>+</sup> T lymphocytes.

*a6* 29. A method for diagnosing a disorder characterized by expression of MAGE-A1 comprising:

contacting a biological sample isolated from a subject with an agent that is specific for the MAGE-A1 HLA class II binding peptide of claim 1 , and  
determining the interaction between the agent and the MAGE-A1 HLA class II binding peptide as a determination of the disorder.

*a7* 33. A method for diagnosing a disorder characterized by expression of [a] the MAGE-A1 HLA class II-binding peptide of claim 1 which forms a complex with an HLA class II molecule, comprising:

contacting a biological sample isolated from a subject with an agent that binds the complex; and

*a7*  
*cont.* determining binding between the complex and the agent as a determination of the disorder.

*a8* 37. A method for treating a subject having a disorder characterized by expression of MAGE-A1, comprising:

administering to the subject an amount of [a] the MAGE-A1 HLA class II-binding peptide of claim 1 sufficient to ameliorate the disorder.

*a9* 43. A method for treating a subject having a disorder characterized by expression of MAGE-A1, comprising:

administering to the subject an amount of [a] the MAGE-A1 HLA class I-binding peptide of claim 1 and an amount of a MAGE-A1 HLA class II-binding peptide sufficient to ameliorate the disorder.

*a10* 50. A method for treating a subject having a disorder characterized by expression of MAGE-A1, comprising:

administering to the subject an amount of an agent which enriches selectively in the subject the presence of complexes of an HLA class II molecule and [a] MAGE-A1 HLA class II-binding peptide of claim 1, sufficient to ameliorate the disorder.

*a11* 57. A method for treating a subject having a disorder characterized by expression of MAGE-A1, comprising:

administering to the subject an amount of autologous CD4<sup>+</sup> T lymphocytes sufficient to ameliorate the disorder, wherein the CD4<sup>+</sup> T lymphocytes are specific for complexes of an HLA class II molecule and [a] the MAGE-A1 HLA class II-binding peptide of claim 1.

*a12* 68. An isolated CD4<sup>+</sup> T lymphocyte which selectively binds a complex of an HLA class II molecule and [a] the MAGE-A1 HLA class II-binding peptide of claim 1.

*a13* 72. An isolated antigen presenting cell which comprises a complex of an HLA class II molecule and [a] the MAGE-A1 HLA class II-binding peptide of claim 1.